These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 23356091)

  • 1. No correlation between plasma NMDA-related glutamatergic amino acid levels and cognitive function in medicated patients with schizophrenia.
    Ohnuma T; Sakai Y; Maeshima H; Higa M; Hanzawa R; Kitazawa M; Hotta Y; Katsuta N; Takebayashi Y; Shibata N; Arai H
    Int J Psychiatry Med; 2012; 44(1):17-27. PubMed ID: 23356091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in plasma glycine, L-serine, and D-serine levels in patients with schizophrenia as their clinical symptoms improve: results from the Juntendo University Schizophrenia Projects (JUSP).
    Ohnuma T; Sakai Y; Maeshima H; Hatano T; Hanzawa R; Abe S; Kida S; Shibata N; Suzuki T; Arai H
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1905-12. PubMed ID: 18835577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in plasma D-serine, L-serine, and glycine levels in treatment-resistant schizophrenia before and after clozapine treatment.
    Yamamori H; Hashimoto R; Fujita Y; Numata S; Yasuda Y; Fujimoto M; Ohi K; Umeda-Yano S; Ito A; Ohmori T; Hashimoto K; Takeda M
    Neurosci Lett; 2014 Oct; 582():93-8. PubMed ID: 25218715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of the ability of clozapine to treat negative symptoms from plasma glycine and serine levels in schizophrenia.
    Sumiyoshi T; Jin D; Jayathilake K; Lee M; Meltzer HY
    Int J Neuropsychopharmacol; 2005 Sep; 8(3):451-5. PubMed ID: 15817136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms.
    Sumiyoshi T; Anil AE; Jin D; Jayathilake K; Lee M; Meltzer HY
    Int J Neuropsychopharmacol; 2004 Mar; 7(1):1-8. PubMed ID: 14720317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different serine and glycine metabolism in patients with schizophrenia receiving clozapine.
    Hons J; Vasatova M; Cermakova E; Doubek P; Libiger J
    J Psychiatr Res; 2012 Jun; 46(6):811-8. PubMed ID: 22502820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma alanine levels increase in patients with schizophrenia as their clinical symptoms improve-Results from the Juntendo University Schizophrenia Projects (JUSP).
    Hatano T; Ohnuma T; Sakai Y; Shibata N; Maeshima H; Hanzawa R; Suzuki T; Arai H
    Psychiatry Res; 2010 May; 177(1-2):27-31. PubMed ID: 20226539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of NMDA receptor-related glutamatergic amino acid levels in peripheral blood of patients with schizophrenia.
    Ohnuma T; Arai H
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jan; 35(1):29-39. PubMed ID: 20828596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Could we use a serum level of glycine as a prognostic factor of its efficacy in schizophrenic patients?].
    Strzelecki D; Rabe-Jabłońska J
    Psychiatr Pol; 2010; 44(3):395-404. PubMed ID: 20672518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
    Buchanan RW; Javitt DC; Marder SR; Schooler NR; Gold JM; McMahon RP; Heresco-Levy U; Carpenter WT
    Am J Psychiatry; 2007 Oct; 164(10):1593-602. PubMed ID: 17898352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relation of plasma glycine, serine, and homocysteine levels to schizophrenia symptoms and medication type.
    Neeman G; Blanaru M; Bloch B; Kremer I; Ermilov M; Javitt DC; Heresco-Levy U
    Am J Psychiatry; 2005 Sep; 162(9):1738-40. PubMed ID: 16135636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Profiling cognitive impairment in treatment-resistant schizophrenia patients.
    Frydecka D; Beszłej JA; Gościmski P; Kiejna A; Misiak B
    Psychiatry Res; 2016 Jan; 235():133-8. PubMed ID: 26706131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
    Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia.
    Hashimoto K; Fukushima T; Shimizu E; Komatsu N; Watanabe H; Shinoda N; Nakazato M; Kumakiri C; Okada S; Hasegawa H; Imai K; Iyo M
    Arch Gen Psychiatry; 2003 Jun; 60(6):572-6. PubMed ID: 12796220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia.
    Weiser M; Heresco-Levy U; Davidson M; Javitt DC; Werbeloff N; Gershon AA; Abramovich Y; Amital D; Doron A; Konas S; Levkovitz Y; Liba D; Teitelbaum A; Mashiach M; Zimmerman Y
    J Clin Psychiatry; 2012 Jun; 73(6):e728-34. PubMed ID: 22795211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia.
    Vinogradov S; Fisher M; Warm H; Holland C; Kirshner MA; Pollock BG
    Am J Psychiatry; 2009 Sep; 166(9):1055-62. PubMed ID: 19570929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor.
    Lane HY; Lin CH; Green MF; Hellemann G; Huang CC; Chen PW; Tun R; Chang YC; Tsai GE
    JAMA Psychiatry; 2013 Dec; 70(12):1267-75. PubMed ID: 24089054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased serum levels of serine enantiomers in patients with depression.
    Hashimoto K; Yoshida T; Ishikawa M; Fujita Y; Niitsu T; Nakazato M; Watanabe H; Sasaki T; Shiina A; Hashimoto T; Kanahara N; Hasegawa T; Enohara M; Kimura A; Iyo M
    Acta Neuropsychiatr; 2016 Jun; 28(3):173-8. PubMed ID: 26512905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia.
    Minzenberg MJ; Poole JH; Benton C; Vinogradov S
    Am J Psychiatry; 2004 Jan; 161(1):116-24. PubMed ID: 14702259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Changes in positive and negative symptoms, general psychopathology in schizophrenic patients during augmentation of antipsychotics with glycine: a preliminary 10-week open-label study].
    Strzelecki D; Rabe-Jabłońska J
    Psychiatr Pol; 2011; 45(6):825-37. PubMed ID: 22335126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.